Treatment with GLP‐1 RA reduced the risk of incident composite adiposity‐related cancers; both for all adiposity‐related cancers (HR 0.86 [95% CI 0.82, 0.89]), and for traditional adiposity‐related cancers (0.86 [0.82, 0.89]) (Table 2). This evidence concerns the gene GLP1R and cancer.